⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8435994 | 0.88 | — | — | |
| SCHEMBL15941586 | 0.88 | — | — | |
| SCHEMBL28946904 | 0.87 | — | — | |
| SCHEMBL29001743 | 0.87 | — | — | |
| SCHEMBL3364907 | 0.86 | CA1 (0.36) | — | |
| SCHEMBL881188 | 0.82 | MAPT (0.39) | — | |
| Biphenyl SCHEMBL11430652 | 0.80 | ALDH1A1 (0.36) | — | |
| SCHEMBL4453883 | 0.73 | — | — | |
| SCHEMBL18496424 | 0.73 | — | — | |
| SCHEMBL29182420 | 0.71 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 705 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139251-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260132406-A1 | RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4715053-A1 | NUCLEIC ACID TARGETING ANGIOTENSINOGEN AND USE THEREOF | SynerK Inc. (KY) | 2026-03-25 | — | — | EP | claimed |
| US-20260078375-A1 | RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-19 | — | — | US | claimed |
| WO-2026043966-A1 | COMPOUNDS AND METHODS FOR MODULATING ALPHA-SYNUCLEIN EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-20260043029-A1 | RNAi Agents for Inhibiting Expression of Thymic Stromal Lymphopoietin (TSLP), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | claimed |
| EP-4689119-A1 | COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-12534728-B2 | RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2026-01-27 | — | — | US | claimed |
| US-20260022379-A1 | Optimized RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-01-22 | — | — | US | claimed |
| WO-2021195467-A2 | RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2021-09-30 | — | — | WO | claimed |
| CN-113164509-A | RNAi agents for inhibiting expression of 17 beta-HSD type 13 (HSD17B13), compositions thereof and methods of use | 箭头药业股份有限公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2021030778-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | claimed |
| WO-2020160163-A1 | COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | WO | claimed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | claimed |
| CN-111107853-A | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | 箭头药业股份有限公司 | 2020-05-05 | — | — | CN | claimed |
| US-10590416-B2 | RNAi agents for inhibiting expression of alpha-ENaC and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2020-03-17 | — | — | US | claimed |
| CN-108516992-B | Method for photocatalytic synthesis of 1-aryl cyclopropyl phosphonate | 宁波工程学院 | 2020-02-07 | — | — | CN | claimed |
| CN-108516992-A | Photocatalytic synthesis at 1- aryl cyclopropyl phosphonate esters method | 宁波工程学院 | 2018-09-11 | — | — | CN | claimed |
| CN-104945433-B | Method for preparing cyclopropyl phosphonate | 苏州大学张家港工业技术研究院 | 2017-03-22 | — | — | CN | claimed |